October | 2010 | GlobeImmune

Phase 2b Study Demonstrates GlobeImmune’s GI-5005 HCV Therapeutic Vaccine Increases Sustained Virologic Response by 12 Percent in Patients Who Previously Failed Therapy with Standard of Care

October 30, 2010

Additional data suggest that cellular immunity may be a fundamental deficit in hardest-to-treat IL28B T/T genotype patients and is corrected by GI-5005 Data to be presented at annual meeting of the American Association for the Study of the Liver Disease … Continue reading →

GlobeImmune Expands GI-5005-02 Phase 2b Trial to Include Additional Treatment Naïve IL28B T/T Subjects with Chronic Genotype 1 HCV

October 28, 2010

LOUISVILLE, Colo., October 28, 2010 – GlobeImmune Inc. today announced the expansion of its Phase 2b clinical trial of GI-5005, an investigational Tarmogen product for the treatment of hepatitis C virus (HCV) infection. The Company previously reported data demonstrating a … Continue reading →

GlobeImmune Announces Late-Breaker Oral Presentation of GI-5005 Prior Non-Responder Data at AASLD 2010 Meeting

October 01, 2010

Immunology data also to be presented in poster session LOUISVILLE, Colo., October 1, 2010 – GlobeImmune Inc. today announced that an abstract related to GI-5005, its Phase 2 investigational hepatitis C virus (HCV) product candidate, has been accepted for a … Continue reading →